Shares of Solaris Resources Inc. (CVE:SLS – Get Free Report) traded down 2.7% during mid-day trading on Tuesday . The stock traded as low as C$5.95 and last traded at C$6.15. 53,313 shares were traded during mid-day trading, a decline of 60% from the average session volume of 132,199 shares. The stock had previously closed at C$6.32.
Analyst Ratings Changes
Separately, HC Wainwright upgraded Solaris Resources to a “strong-buy” rating in a report on Monday, August 12th.
Get Our Latest Analysis on Solaris Resources
Solaris Resources Stock Down 2.7 %
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Featured Articles
- Five stocks we like better than Solaris Resources
- What Investors Need to Know About Upcoming IPOs
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Dividend Payout Ratio Calculator
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- 3 Healthcare Dividend Stocks to Buy
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
